关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025年 8 月 15 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 100%的股权和法人股东台州市梓铭贸易有限公司 100%的股权,为公司实际控 制人。 本家族全体成员于 2025 年 8 月 15 日收到你公司发来的《关于济 ...

●经公司自查并书面征询控股股东及实际控制人，截至本公告披露日，公司 不存在应披露而未披露的重大事项。 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险，敬请广大投 资者理性决策，审慎投资。 一、股票交易异常波动的具体情况 证券代码：603222 证券简称：济民健康 公告编号：2025-037 济民健康管理股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●公司股票交易于2025年8月13日、8月14日、8月15日连续三个交易日内收盘 价格涨幅偏离值累计超过20%，属于《上海证券交易所交易规则》规定的股票交易 异常波动情形。 济民健康管理股份有限公司（以下简称"公司"）股票于 2025 年 8 月 13 日、 8 月 14 日、8 月 15 日连续三个交易日内收盘价格涨幅偏离值累计达到 20%，根据 《上海证券交易所交易规则》的相关规定，属于股票交易异常波动。 二、公司关注并核实的相关情况 针对股票交易异常波动情况，公司对有关事项进行了核查，现将有关情况说 明如 ...

Group 1 - The medical device sector has regained momentum, with the medical device ETF (562600) rising by 1.08%, and key holdings like Sainuo Medical increasing by 13.72% [1] - The medical device sector outperformed the pharmaceutical and biological sector, with a growth rate of 14.27%, ranking second among six sub-industries, and surpassing the pharmaceutical sector and the CSI 300 index by 1.38 and 10.74 percentage points respectively [1] - Analysts believe the medical device industry is poised for multi-dimensional development through technological platformization, AI diagnostics expansion, and consumer healthcare advancements, indicating a shift from scale expansion to higher-level development [1] Group 2 - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device industry, tracking the CSI All Share Medical Device Index [2] - The index comprises 100 representative listed companies in core medical fields, with the medical device sector accounting for 89.34% of the index, highlighting its concentrated structure and ability to capture industry growth [2]

证券之星消息，8月15日医疗器械板块较上一交易日上涨1.42%，赛诺医疗领涨。当日上证指数报收于 3696.77，上涨0.83%。深证成指报收于11634.67，上涨1.6%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688108 | 赛诺医疗 | 34.57 | 13.72% | 71.56万 | 23.31亿 | | 603222 | 济民健康 | 8.91 | 10.00% | 101.34万 | 8.73亿 | | 002551 | 尚荣医疗 | 4.87 | 9.93% | 51.16万 | 2.46亿 | | 688755 | 汉邦科技 | 49.43 | 7.67% | - 3.57万 | 1.74亿 | | 300246 | 宝莱特 | 10.14 | 6.85% | 37.98万 | 3.88 Z | | 300942 | 易瑞生物 | 13.08 | 6.43% | 17.46万 | 2.25亿 | | 300677 | 英科医疗 | 37 ...

Group 1 - The core viewpoint of the articles highlights a positive trend in the medical device sector, with major stocks experiencing significant gains, indicating a recovery in the market [1] - The medical device index ETF (159898) showed a morning rebound with a rise of 1.03%, attracting over 15 million yuan in net subscriptions, reflecting investor confidence [2] - Future growth in the medical device industry is expected to be driven by technological advancements, AI diagnostics, and the expansion of consumer healthcare, transitioning to a higher development stage [2] Group 2 - Financial institutions like Caixin Securities maintain a "leading the market" rating for the medical device sector, anticipating high-quality development and long-term investment opportunities [2] - The impact of centralized procurement in high-cost areas is gradually diminishing, with some products benefiting from renewed contracts, suggesting a potential for volume and price increases in the coming years [2] - The medical device index ETF (159898) has seen a cumulative net value increase of 22.82% over the past year, outperforming its benchmark by 5.99%, ranking first among similar index ETFs [2][3]

Core Viewpoint - Jimin Health has experienced a significant stock price increase of 10.00%, achieving a price of 8.91 yuan and a total market capitalization of 4.679 billion yuan, indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Strategic Collaborations - The company has entered into a strategic partnership with Dabo Bio in the field of cell gene therapy, focusing on the development of oncolytic virus drugs, which aligns with the biotechnology sector within the healthcare industry [1] - Jimin Health is participating in an AI entrepreneurship development fund, integrating AI with medical technology, thus tapping into the emerging trend of AI and healthcare convergence [1] Group 2: Market Confidence Initiatives - The company has announced a share repurchase plan worth 100-200 million yuan, aimed at strengthening market confidence and supporting the buyback concept [1] Group 3: Business Segments - Jimin Health is primarily involved in several key sectors including biotechnology, artificial intelligence, medical devices, medical services, and share buybacks, reflecting a diversified approach to growth and investment opportunities [1]

济民健康(603222)今日涨停，全天换手率17.99%，成交额7.42亿元，振幅11.88%。龙虎榜数据显示，营 业部席位合计净买入465.46万元。 上交所公开信息显示，当日该股因日涨幅偏离值达10.51%上榜，营业部席位合计净买入465.46万元。 融资融券数据显示，该股最新（8月13日）两融余额为1.62亿元，其中，融资余额为1.62亿元，融券余额 为5.81万元。近5日融资余额合计增加1299.80万元，增幅为8.74%。融券余额合计增加5.68万元，增幅 4156.52%。 4月29日公司发布的一季报数据显示，一季度公司共实现营业收入1.81亿元，同比下降22.49%，实现净 利润-1363.65万元。 7月12日公司发布上半年业绩预告，预计实现净利润-5500.00万元至-4600.00万元，同比变动区间 为-316.15%~-280.78%。（数据宝） 济民健康8月14日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 东方财富证券股份有限公司上海东方路证券营 ...

证券之星消息，8月14日医疗器械板块较上一交易日下跌2.16%，利德曼领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300289 | 利德曼 | 10.06 | -11.21% | 106.05万 | | 10.85 Z | | 300981 | 中红医疗 | 16.00 | -9.91% | 26.13万 | | 4.31亿 | | 688677 | 海泰新光 | 45.30 | -7.93% | 4.91万 | | 2.28亿 | | 301235 | や康浩浄 | 29.72 | -7.90% | 15.14万 | | 4.42亿 | | 832278 | 鹿得医疗 | 11.23 | -7.88% | 9.33万 | | 1.07亿 | | 688212 | 澳华内镜 | 49.14 | -7.79% | 4.70万 | | 2.34亿 ...

一、回购股份的基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 济民健康管理股份有限公司董事会 2025年8月1日 济民健康管理股份有限公司(以下简称"公司")于2025年3月28日召开第五届董事会第十七次会议，审议 通过了《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金及金融机构借款以集 中竞价交易方式回购公司股份，回购价格不超过人民币10元/股（含）；回购资金总额不低于人民币 10,000万元（含）且不超过人民币20,000万元（含）；回购期限为自董事会审议通过回购方案之日起不 超过12个月。具体内容详见公司于2025年3月29日在上海证券交易所网站披露的《公司关于 ...

Group 1 - The stock price of Jimin Health is reported at 6.92 yuan, down 0.15 yuan from the previous trading day, representing a decline of 2.12% [1] - The trading volume for the day was 89,780 hands, with a transaction amount of 0.63 million yuan [1] - Jimin Health operates in the pharmaceutical manufacturing industry, with its main business segments including pharmaceutical manufacturing, medical services, and pharmaceutical trade [1] Group 2 - According to the 2024 annual report, the pharmaceutical manufacturing business accounts for 55.95% of total revenue, while medical services contribute 41.43% [1] - As of July 31, the company has repurchased 2.01 million shares, representing 0.38% of the total share capital, with a repurchase amount of 12.09 million yuan [1] - In the first quarter of 2025, the company reported revenue of 181 million yuan, with a net profit loss of 13.64 million yuan [1] Group 3 - Data shows that on July 31, Jimin Health experienced a net outflow of main funds amounting to 16.57 million yuan, which is 0.46% of the circulating market value [1]